In the last three months, 15 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 2.78% from the previous average price target of $98.20.

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent...